Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 10—October 2009

Research

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy

Kevin L. WinthropComments to Author , Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue
Author affiliations: Oregon Health and Sciences University, Portland, Oregon, USA (K.L. Winthrop, E. Chang, S. Yamashita); US Public Health Service, Washington, DC, USA (M.F. Iademarco); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P.A. LoBue)

Main Article

Table 3

Characteristics of 105 pulmonary and nonpulmonary anti–TNF-α therapy–associated cases of NTM disease, US Food and Drug Administration MedWatch database, 1999–2006*

Characteristic Pulmonary (n = 59), no. (%) Extrapulmonary (n = 46), no. (%)
Mycobacterium avium 43 (73) 9 (20)†
RGM 6 (10) 15 (33)†
Age, y 61 63
Female patient 41 (73) 25 (54)†
Rheumatoid arthritis 48 (81) 25 (54)†
Infliximab 40 (68) 33 (72)
Etanercept 13 (22) 12 (26)

*TNF-α, tumor necrosis factor-α; NTM, nontuberculous mycobacteria; RGM, rapidly growing mycobacteria.
†p<0.05 for comparison of pulmonary disease and extrapulmonary disease.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO